Literature DB >> 21454665

SYT-SSX1 (synovial sarcoma translocated) regulates PIASy ligase activity to cause overexpression of NCOA3 protein.

Yin Sun1, Juanita Perera, Brian P Rubin, Jiaoti Huang.   

Abstract

Chromosomal translocations are a major source of genetic abnormalities causally linked to certain malignancies. Synovial sarcoma is an aggressive soft tissue tumor characterized by a chromosomal translocation between chromosome 18 and X, generating oncoproteins such as SYT-SSX1 and SYT-SSX2. The molecular mechanism underlying the oncogenic potential of SYT-SSX1/2 is not clear. Here we show that SYT-SSX1 leads to up-regulation of NCOA3, a protein critical for the formation of various cancers. The increase of NCOA3 is essential for SYT-SSX1-mediated synovial sarcoma formation. SYT-SSX1 does so by increasing the sumoylation of NCOA3 through interaction with a SUMO E3 ligase, PIASy, as well as the sumoylation of NEMO. NEMO has also been shown to physically interact with NCOA3. Increased sumoylation of NCOA3 leads to its increased steady state level and nuclear localization. Our findings represent the first example that an oncoprotein directly regulates substrate modification by a SUMO E3 ligase, and leads to overexpression of a protein essential for tumor formation. Such a mechanistic finding provides an opportunity to design specific therapeutic interventions to treat synovial sarcoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454665      PMCID: PMC3099678          DOI: 10.1074/jbc.M110.176693

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha.

Authors:  Meelad M Dawlaty; Liviu Malureanu; Karthik B Jeganathan; Esther Kao; Claudio Sustmann; Samuel Tahk; Ke Shuai; Rudolf Grosschedl; Jan M van Deursen
Journal:  Cell       Date:  2008-04-04       Impact factor: 41.582

2.  Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

Authors:  Xiao-Wei Zhang; Xiao-Jing Yan; Zi-Ren Zhou; Fei-Fei Yang; Zi-Yu Wu; Hong-Bin Sun; Wen-Xue Liang; Ai-Xin Song; Valérie Lallemand-Breitenbach; Marion Jeanne; Qun-Ye Zhang; Huai-Yu Yang; Qiu-Hua Huang; Guang-Biao Zhou; Jian-Hua Tong; Yan Zhang; Ji-Hui Wu; Hong-Yu Hu; Hugues de Thé; Sai-Juan Chen; Zhu Chen
Journal:  Science       Date:  2010-04-09       Impact factor: 47.728

3.  Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.

Authors:  Arthur C-K Chung; Suoling Zhou; Lan Liao; Jean Ching-Yi Tien; Norman M Greenberg; Jianming Xu
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

4.  Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.

Authors:  Ganesh S Palapattu; Chengyu Wu; Christopher R Silvers; Heather B Martin; Karin Williams; Linda Salamone; Timothy Bushnell; Li-Shan Huang; Qi Yang; Jiaoti Huang
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

5.  RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.

Authors:  Michael H Tatham; Marie-Claude Geoffroy; Linnan Shen; Anna Plechanovova; Neil Hattersley; Ellis G Jaffray; Jorma J Palvimo; Ronald T Hay
Journal:  Nat Cell Biol       Date:  2008-04-13       Impact factor: 28.824

6.  Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.

Authors:  Valérie Lallemand-Breitenbach; Marion Jeanne; Shirine Benhenda; Rihab Nasr; Ming Lei; Laurent Peres; Jun Zhou; Jun Zhu; Brian Raught; Hugues de Thé
Journal:  Nat Cell Biol       Date:  2008-04-13       Impact factor: 28.824

7.  Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway.

Authors:  Xiaotao Li; Larbi Amazit; Weiwen Long; David M Lonard; John J Monaco; Bert W O'Malley
Journal:  Mol Cell       Date:  2007-06-22       Impact factor: 17.970

8.  Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1.

Authors:  Ping Yi; Qin Feng; Larbi Amazit; David M Lonard; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Mol Cell       Date:  2008-02-29       Impact factor: 17.970

9.  Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.

Authors:  J Clark; P J Rocques; A J Crew; S Gill; J Shipley; A M Chan; B A Gusterson; C S Cooper
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330

10.  The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways.

Authors:  Masashi Kajiro; Ryuichi Hirota; Yuka Nakajima; Kaori Kawanowa; Kae So-ma; Ichiaki Ito; Yuri Yamaguchi; Sho-hei Ohie; Yasuhito Kobayashi; Yuko Seino; Miwako Kawano; Yoh-ichi Kawabe; Hiroyuki Takei; Shin-ichi Hayashi; Masafumi Kurosumi; Akiko Murayama; Keiji Kimura; Junn Yanagisawa
Journal:  Nat Cell Biol       Date:  2009-02-08       Impact factor: 28.824

View more
  3 in total

1.  Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation.

Authors:  Boxiao Ding; Yin Sun; Jiaoti Huang
Journal:  J Biol Chem       Date:  2012-03-12       Impact factor: 5.157

2.  Systems-Level Mapping of Cancer Testis Antigen 1b/a to Sarcoma Pathways Identifies Activated Ran Binding-2 E3 SUMO-Protein Ligase and Transducin-Like Enhancer Protein 1.

Authors:  Nikolaos A Papanikolaou; Prodromos Hytiroglou; Pavlina Pantelidou; Athanasios G Papavassiliou; Lloyd L Old
Journal:  Front Genet       Date:  2022-05-18       Impact factor: 4.772

3.  PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells.

Authors:  W Chien; K L Lee; L W Ding; P Wuensche; H Kato; N B Doan; L Poellinger; J W Said; H P Koeffler
Journal:  Br J Cancer       Date:  2013-09-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.